Dupree Financial Group LLC Makes New $3 Million Investment in Humana Inc. (NYSE:HUM)

Dupree Financial Group LLC bought a new position in shares of Humana Inc. (NYSE:HUM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,841 shares of the insurance provider’s stock, valued at approximately $3,004,000. Humana comprises 1.4% of Dupree Financial Group LLC’s portfolio, making the stock its 25th largest holding.

Several other institutional investors and hedge funds also recently modified their holdings of HUM. Sanctuary Advisors LLC acquired a new stake in Humana during the second quarter worth about $3,341,000. AMF Tjanstepension AB raised its holdings in Humana by 166.8% in the third quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after buying an additional 25,041 shares during the period. Park Avenue Securities LLC lifted its position in Humana by 17.3% during the third quarter. Park Avenue Securities LLC now owns 4,857 shares of the insurance provider’s stock valued at $1,538,000 after buying an additional 718 shares in the last quarter. Czech National Bank grew its stake in Humana by 6.8% during the third quarter. Czech National Bank now owns 24,527 shares of the insurance provider’s stock worth $7,769,000 after buying an additional 1,564 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Humana by 78.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,352 shares of the insurance provider’s stock valued at $428,000 after acquiring an additional 593 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.29% of the company’s stock.

Humana Trading Down 0.1 %

NYSE HUM opened at $292.82 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a 50-day simple moving average of $275.36 and a 200-day simple moving average of $301.04. The firm has a market capitalization of $35.26 billion, a PE ratio of 25.94, a price-to-earnings-growth ratio of 2.21 and a beta of 0.56.

Analyst Ratings Changes

Several research firms have commented on HUM. Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and cut their price objective for the company from $519.00 to $253.00 in a research report on Monday, October 7th. Morgan Stanley upped their price target on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Stephens reiterated an “equal weight” rating and set a $250.00 price objective on shares of Humana in a research note on Wednesday, October 9th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and raised their price target for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Finally, Barclays boosted their price objective on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 22nd. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $297.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.